Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1

Opinion
Video

Samer Al'Hadidi, MD, provides an overview of recent updates presented at ASCO 2024 from the MajesTEC-1 trial evaluating teclistamab in patients with relapsed/refractory multiple myeloma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question:

      • Please discuss the long-term follow-up from the phase 1/2 MajesTEC-1 study investigating teclistamab in relapsed/refractory multiple myeloma.